VNDAHealthcare · BiotechnologyThe 4 Wall Street analysts covering Vanda Pharmaceuticals, Inc. hold a median 12-month price target of $12 — +125.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 12 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Vanda Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (26): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VNDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +125.9% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | $17 → $12 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $21 → $20 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $21 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Mar 2026 | Truist Securities | Initiates | Buy | — |
| 23 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Dec 2025 | B. Riley Securities | Maintains | Buy | — |
| 31 Dec 2025 | Jefferies | Maintains | Hold | — |
| 19 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2025 | B. Riley Securities | Initiates | Buy | — |
| 30 Oct 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2025 | Cantor Fitzgerald | Assumes | Overweight | $13 |
| 7 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VNDA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Vanda Pharmaceuticals, Inc. returned +10.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 6% of US stocks
Cheaper than 61% of US stocks
Cheaper than 70% of US stocks
Cheaper than 66% of US stocks
Higher than 21% of US stocks
Higher than 32% of US stocks
Higher than 97% of US stocks
Higher than 12% of US stocks
Higher than 5% of US stocks
Higher than 16% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vanda Pharmaceuticals, Inc. has a market value of $307.8M and an enterprise value of $160.6M.
Revenue in the twelve months to 30 June 2026: $215.7M. The latest quarter shrank 3.9% year on year.
Net income over the same four quarters: −$274.9M, a −127.4% net margin.
Diluted earnings per share, trailing twelve months: $−4.63.
Free cash flow in the twelve months to 30 June 2026: −$153.0M.
Trailing P/E: 126.0×; forward P/E: 25.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Vanda Pharmaceuticals, Inc. employs 533 people — $405K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vanda Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vanda Pharmaceuticals announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026. The announcement was made via press release on September 2, 2026.
Why it matters — Participation at investor conferences gives Vanda management a platform to present company updates and engage with investors and analysts.
Vanda Pharmaceuticals announced that the European Commission granted Orphan Designation to its investigational drug imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), based on a positive opinion from the EMA's Committee for Orphan Medicinal Products. This is the first orphan designation granted by the European Commission for a GPP treatment in the EU, complementing previous US FDA and Japanese designations.
Why it matters — This extends regulatory recognition of imsidolimab to a third major region, strengthening the drug's development position for a severe, potentially life-threatening skin disease.
Vanda Pharmaceuticals announced that the NEREUS-branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, will race this weekend in the inaugural Freedom 250 Grand Prix in Washington, D.C.
Why it matters — The announcement highlights Vanda's continued sponsorship of the NEREUS brand through the IndyCar racing program, raising brand visibility for the company.
Zacks Investment Research highlighted VNDA among four psoriasis drug stocks to watch during Psoriasis Awareness Month 2026, noting the company offers psoriasis opportunities spanning approved therapies, late-stage candidates, and earlier-stage programs.
Why it matters — The mention underscores that VNDA is one of a select group of companies with psoriasis-related drug assets across multiple stages of development, which may draw investor attention during Psoriasis Awareness Month.
Vanda Pharmaceuticals held its Q2 2026 earnings call, and Seeking Alpha published a transcript of the event covering the company's quarterly results and management commentary.
Why it matters — A VNDA watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly financial performance and management's outlook.
The 4 Wall Street analysts covering Vanda Pharmaceuticals, Inc. have a median 12-month price target of $12, with estimates ranging from $5.75 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Vanda Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vanda Pharmaceuticals, Inc. 44 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Vanda Pharmaceuticals, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +125.9% from the last close, and Ticker Nerd's factor model ranks Vanda Pharmaceuticals, Inc. 44 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vanda Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.75 to $20 over the next 12 months.
Vanda Pharmaceuticals, Inc. returned +10.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs.
The most recent item we track (PRNewsWire, 2 Sept 2026): "Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences". Vanda Pharmaceuticals announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026. The announcement was made via press release on September 2, 2026.
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs. The company’s marketed products include HETLIOZ and Fanapt, while PONVORY adds a presence in immune-related therapeutics. Vanda also works on specialty medicines for rare diseases and other targeted indications, using genetics and genomics to guide drug discovery and clinical development. With a concentrated product mix and a research-driven model, Vanda Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market by addressing niche patient populations where treatment options may be limited.
CEO Dr. Mihael H. Polymeropoulos M.D. · 533 employees · United States · https://www.vandapharma.com
